72139
document
Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection . This study aims to identify patient characteristics that predict effective eltrombopag dosage for the treatment of Hepatitis C virus ( HCV ) -related thrombocytopenia . Demographic , clinical and genetic data collected from thrombocytopenic patients ( n = 1463 , age ≥ 18 years ) with chronic HCV infection who were able to achieve a target platelet count of > 90 × 10 ( 9 ) /L following eltrombopag treatment . Patients were categorized into four groups ( 25 , 50 , 75 , and 100 mg ) based on the eltrombopag dose needed to achieve the target platelet count . Eltrombopag dose predictors were identified using a two stage approach . First , bivariate analysis , using anova for continuous variables and Chi-square test for categorical variables , was performed to identify possible predictors of eltrombopag dose ( P < 0.05 ) . Second , ordinal logistic regression with stepwise addition followed by backward deletion was then performed using predictors identified in bivariate analysis step to produce final model containing independent predictors at P < 0.05 . Ordinal logistic model identified several predictors of eltrombopag dose . Predictors of higher eltrombopag dose include : having a HCV genotype 2 or 3 , being Central/South Asian , being White ( Caucasian or European heritage ) , increased weight , and increased spleen length . Predictors of lower eltrombopag dose include : female gender , increased age , having a higher ALP plasma concentration , increased creatinine clearance , increased baseline lymphocytes count , and increased baseline platelet count . In conclusion , this study identified patient characteristics that predict effective eltrombopag dose for the treatment of HCV-related thrombocytopenia . Early selection of the optimal eltrombopag dose expedites the initiation of antiviral therapy . This is expected to improve the antiviral therapy outcome before the patient progress into liver decompensation .
72140
Outcome_Physical
include : having a HCV genotype 2 or 3 , being Central/South Asian , being White ( Caucasian or European heritage ) , increased weight , and increased spleen length
72141
Outcome_Physical
include : female gender , increased age , having a higher ALP plasma concentration , increased creatinine clearance , increased baseline lymphocytes count , and increased baseline platelet count
72142
Participant_Condition
thrombocytopenic subjects with hepatitis C virus infection
72143
Participant_Condition
thrombocytopenic
72144
Participant_Sample-size
n = 1463
72145
Participant_Age
age ≥ 18 years
72146
Participant_Condition
HCV infection